Top

European Journal of Nuclear Medicine and Molecular Imaging

Published in:

Open Access 17-03-2022 | Positron Emission Tomography | Short Communication

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Published in: European Journal of Nuclear Medicine and Molecular Imaging | Issue 9/2022

Abstract

Purpose

The prognostic value of PSMA intensity on PSMA PET/CT due to underlying biology and subsequent clinical implications is an emerging topic of interest. We sought to investigate whether primary tumour PSMA PET intensity contributes to pre- and post-operative prediction of oncological outcomes following radical prostatectomy.

Methods

We performed a retrospective cohort study of 848 men who underwent all of multiparametric MRI (mpMRI), transperineal prostate biopsy, and ⁶⁸ Ga-PSMA PET/CT prior to radical prostatectomy. PSMA intensity, quantified as maximum standard uptake value (SUVmax), and other clinical variables were considered relative to post-operative biochemical recurrence-free survival (BRFS) using Cox regression and Kaplan–Meier analysis.

Results

After a median follow-up of 41 months, 219 events occurred; the estimated 3-year BRFS was 79% and the 5-year BRFS was 70%. Increasing PSMA intensity was associated with less favourable BRFS overall (Log rank p < 0.001), and within subgroups of Gleason score category (Log rank p < 0.03). PSMA intensity was significantly associated with shorter time to biochemical recurrence, after adjusting for pre-operative (HR per 5-unit SUVmax increase = 1.15) and post-operative (HR per 5-unit SUVmax increase = 1.10) parameters.

Conclusion

These results in a large series of patients confirm PSMA intensity to be a novel, independent prognostic factor for BRFS.

Available only for authorised users

Mottet N, Bellmunt J, Briers E, Bolla M, Bourke L, Cornford P, et al. EAU – ESTRO – ESUR – SIOG Guidelines on Prostate Cancer. Arnhem, The Netherlands: EAU Guidelines Office; 2020.

Mazzone E, Gandaglia G, Ploussard G, Marra G, Valerio M, Campi R, et al. Risk stratification of patients candidate to radical prostatectomy based on clinical and multiparametric magnetic resonance imaging parameters: development and external validation of novel risk groups. Eur Urol. 2021. https://doi.org/10.1016/j.eururo.2021.07.027.CrossRefPubMed

Ferraro DA, Muehlematter UJ, Garcia Schüler HI, Rupp NJ, Huellner M, Messerli M, et al. (68)Ga-PSMA-11 PET has the potential to improve patient selection for extended pelvic lymph node dissection in intermediate to high-risk prostate cancer. Eur J Nucl Med Mol Imaging. 2020;47:147–59. https://doi.org/10.1007/s00259-019-04511-4.CrossRefPubMed

Roberts MJ, Morton A, Donato P, Kyle S, Pattison DA, Thomas P, et al. (68)Ga-PSMA PET/CT tumour intensity pre-operatively predicts adverse pathological outcomes and progression-free survival in localised prostate cancer. Eur J Nucl Med Mol Imaging. 2021;48:477–82. https://doi.org/10.1007/s00259-020-04944-2.CrossRefPubMed

Wang H, Amiel T, Würnschimmel C, Langbein T, Steiger K, Rauscher I, et al. PSMA-ligand uptake can serve as a novel biomarker in primary prostate cancer to predict outcome after radical prostatectomy. EJNMMI Res. 2021;11. https://doi.org/10.1186/s13550-021-00818-2

Franklin A, Yaxley WJ, Raveenthiran S, Coughlin G, Gianduzzo T, Kua B, et al. Histological comparison between predictive value of preoperative 3-T multiparametric MRI and (68) Ga-PSMA PET/CT scan for pathological outcomes at radical prostatectomy and pelvic lymph node dissection for prostate cancer. BJU Int. 2021;127:71–9. https://doi.org/10.1111/bju.15134.CrossRefPubMed

McBean R, Kumari A, McEwan L, Walters J, Wong D. Combined intravenous urogram and 68Ga-PSMA PET/ CT for improved staging and restaging of prostate cancer. J Clin Imaging Sci. 2020;10:67. https://doi.org/10.25259/jcis_88_2020.CrossRefPubMedPubMedCentral

Bolla M, van Poppel H, Tombal B, Vekemans K, Da Pozzo L, de Reijke TM, et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet. 2012;380:2018–27. https://doi.org/10.1016/S0140-6736(12)61253-7.CrossRefPubMed

Paschalis A, Sheehan B, Riisnaes R, Rodrigues DN, Gurel B, Bertan C, et al. Prostate-specific membrane antigen heterogeneity and DNA repair defects in prostate cancer. Eur Urol. 2019;76:469–78. https://doi.org/10.1016/j.eururo.2019.06.030.CrossRefPubMedPubMedCentral

10.

Hupe MC, Philippi C, Roth D, Kümpers C, Ribbat-Idel J, Becker F, et al. Expression of Prostate-specific membrane antigen (PSMA) on biopsies is an independent risk stratifier of prostate cancer patients at time of initial diagnosis. Front Oncol. 2018;8:623. https://doi.org/10.3389/fonc.2018.00623.CrossRefPubMedPubMedCentral

Title: Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy
Publication date: 17-03-2022
Keywords: Positron Emission Tomography
Prostatectomy
Prostatectomy
Published in: European Journal of Nuclear Medicine and Molecular Imaging / Issue 9/2022
Print ISSN: 1619-7070
Electronic ISSN: 1619-7089
DOI: https://doi.org/10.1007/s00259-022-05756-2

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Primary tumour PSMA intensity is an independent prognostic biomarker for biochemical recurrence-free survival following radical prostatectomy

Abstract

Purpose

Methods

Results

Conclusion

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 9/2022

Deep learning-based image reconstruction and post-processing methods in positron emission tomography for low-dose imaging and resolution enhancement

Image-level trajectory inference of tau pathology using variational autoencoder for Flortaucipir PET

Correction to: Effects of chronic voluntary alcohol consumption on PDE10A availability: a longitudinal behavioral and [18F]JNJ42259152 PET study in rats

Non-prostate cancer tumours: incidence on 18F-DCFPyL PSMA PET/CT and uptake characteristics in 1445 patients

“Virtual” attenuation correction: improving stress myocardial perfusion SPECT imaging using deep learning

Molecular fluorophores for in vivo bioimaging in the second near-infrared window